Integrating the Rabies Vaccine RabiVax-S and VaxiRab-N into Tanzania's Routine Immunization Schedule for the exposed population: A Recommendation from the Tanzania Immunization Technical Advisory Group
Tanzania Journal of Health Research · 03.03.2026 · 27 (1) · 3086-95
DOI: 10.4314/thrb.v27i1.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tanzania Journal of Health Research, online erschienen am 03.03.2026. Verfasst von Fidelis Bugoye und 26 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Rabies, a fatal zoonotic disease, is still an important public health challenge in Tanzania and has been causing an estimated 350-800 human deaths annually, with children under 15 years of age accounting for over half of the cases. This document reviews evidence data to guide the introduction of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) using cell-culture or embryonated egg-based rabies vaccines (CCEEVs), precisely RabiVax-S® and VaxiRab-N®, into Tanzania’s routine immunization program.
Methods
The Tanzania Immunization Technical Advisory Group (TITAG) met from August to September 2024 to discuss the evidence supporting the introduction of a two-site intradermal (ID) schedule (0, 3 and 7 days) (RabiVax-S®/VaxiRab-N®). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was used to assess the quality of available evidence for vaccine efficacy, effectiveness, safety, cost-effectiveness, and programmatic feasibility. Data were obtained from randomized controlled trials, systematic reviews, WHO position papers, GAVI recommendations, and operational research.
Results
RabiVax-S® and VaxiRab-N® are highly immunogenic CCEEVs with a clinical efficacy of nearly 100% for both PrEP and PEP. These vaccines induce durable immunological memory. Safety profiles are excellent, with only mild, transient side effects; contraindications include a history of allergic reactions to previous doses. From a cost perspective, the intradermal schedule was more affordable than intramuscular IM schedules. Integration of the program through established health information systems would be possible but needs strategically focused effort in regions with low coverage and healthcare worker training and a robust One Health approach. Recommendation: TITAG recommended the integration of RabiVax-S®/VaxiRab-N® (2-site ID on days 0, 3, and 7) vaccine into the routine vaccination schedule for exposed populations in addition to the recommended standard wound management.
Zitieren
APA
Bugoye, F., Hassan, F., Mirambo, M. M., Ntinginya, N. E., Mwanyika-Sando, M., Kabalamu, F. S., Kasonogo, R., Mkhoi, M. L., Michael, F. S., Bahati, A., Kaale, E., Chai, J. J., Joachim, G., Mujuni, D., Ndiyo, D., Mahmoud, S., Ali, A. S., Mdachi, J., Nyamungumi, Z., …, & Misinzo, G. (2026). Integrating the Rabies Vaccine RabiVax-S and VaxiRab-N into Tanzania's Routine Immunization Schedule for the exposed population: A Recommendation from the Tanzania Immunization Technical Advisory Group. Tanzania Journal of Health Research, 27(1), 3086-95. https://doi.org/10.4314/thrb.v27i1.5
Vancouver
Bugoye F, Hassan F, Mirambo MM, Ntinginya NE, Mwanyika-Sando M, Kabalamu FS, et al. Integrating the Rabies Vaccine RabiVax-S and VaxiRab-N into Tanzania's Routine Immunization Schedule for the exposed population: A Recommendation from the Tanzania Immunization Technical Advisory Group. Tanzania Journal of Health Research. 2026;27(1):3086-95. doi:10.4314/thrb.v27i1.5
BibTeX
@article{Bugoye2026,
author = {Bugoye, Fidelis and Hassan, Farida and Mirambo, Mariam M and Ntinginya, Nyanda E. and Mwanyika-Sando, Mary and Kabalamu, Florence S. and Kasonogo, Richard and Mkhoi, Mkhoi L. and Michael, Fausta S. and Bahati, Andrew and Kaale, Eliangiringa and Chai, John J. and Joachim, Georgina and Mujuni, Delphinus and Ndiyo, Daniel and Mahmoud, Salma and Ali, Ali Salim and Mdachi, Joseph and Nyamungumi, Zainabu and Bukagile, Abella and Tinuga, Florian and Kyesi, Furaha and Kilonzo, Semvua and Morona, Domenica and Minzi, Omary and Mshana, Stephen Eliatosha and Misinzo, Gerald},
title = {Integrating the Rabies Vaccine RabiVax-S and VaxiRab-N into Tanzania's Routine Immunization Schedule for the exposed population: A Recommendation from the Tanzania Immunization Technical Advisory Group},
journal = {Tanzania Journal of Health Research},
year = {2026},
volume = {27},
number = {1},
pages = {3086--95},
doi = {10.4314/thrb.v27i1.5}
}
EUVIMED